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IMPORTANCE Whether the administration of luteinizing hormone–releasing hormone
analogues (LHRHa) during chemotherapy is a reliable strategy to preserve ovarian function is
controversial owing to both the lack of data on long-term ovarian function and pregnancies
and the safety concerns about the potential negative interactions between endocrine therapy
and chemotherapy.
OBJECTIVE To evaluate long-term results of LHRHa-induced ovarian suppression during
breast cancer chemotherapy.
DESIGN, SETTING, AND PARTICIPANTS Parallel, randomized, open-label, phase 3 superiority
trial conducted at 16 Italian sites. Between October 2003 and January 2008, 281
premenopausal womenwith stage I to III hormone receptor–positive or hormone
receptor–negative breast cancer were enrolled. Last annual follow-up was June 3, 2014.
INTERVENTIONS Patients were randomized to receive adjuvant or neoadjuvant
chemotherapy alone (control group) or chemotherapy plus triptorelin (LHRHa group).
MAIN OUTCOMES ANDMEASURES The primary planned end point was incidence of
chemotherapy-induced early menopause. Post hoc end points were long-term ovarian
function (evaluated by yearly assessment of menstrual activity and defined as resumed by
the occurrence of at least 1 menstrual cycle), pregnancies, and disease-free survival (DFS).
RESULTS A total of 281 women (median age, 39 [range, 24-45] years) were randomized.
Median follow-up was 7.3 years (interquartile range, 6.3-8.2 years). The 5-year cumulative
incidence estimate of menstrual resumption was 72.6% (95% CI, 65.7%-80.3%) among the
148 patients in the LHRHa group and 64.0% (95% CI, 56.2%-72.8%) among the 133 patients
in the control group (hazard ratio [HR], 1.28 [95% CI, 0.98-1.68]; P = .07; age-adjusted HR,
1.48 [95% CI, 1.12-1.95]; P = .006). Eight pregnancies (5-year cumulative incidence estimate
of pregnancy, 2.1% [95% CI, 0.7%-6.3%]) occurred in the LHRHa group and 3 (5-year
cumulative incidence estimate of pregnancy, 1.6% [95% CI, 0.4%-6.2%]) in the control group
(HR, 2.56 [95% CI, 0.68-9.60]; P = .14; age-adjusted HR, 2.40 [95% CI, 0.62-9.22]; P = .20).
Five-year DFS was 80.5% (95% CI, 73.1%-86.1%) in the LHRHa group and 83.7% (95% CI,
76.1%-89.1%) in the control group (LHRHa vs control: HR, 1.17 [95% CI, 0.72-1.92]; P = .52).
CONCLUSIONSANDRELEVANCE Amongpremenopausalwomenwith either hormone receptor–
positiveor hormone receptor–negativebreast cancer, concurrent administrationof triptorelin
and chemotherapy, comparedwith chemotherapy alone,was associatedwithhigher long-term
probability of ovarian function recovery,without a statistically significant difference inpregnancy
rate. Therewasno statistically significant difference inDFS forwomenassigned to triptorelin and
those assigned to chemotherapy alone, although studypowerwas limited.
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T hemajority of youngwomenwith invasive breast can-cerarecandidates to receivebothchemotherapyanden-docrinetherapy.1Ovarianfunction lossand impairedfer-
tility are possible consequences of anticancer treatments and
have a negative impact on global health of young survivors of
breast cancer.2 Moreover, fertility concerns can affect treat-
ment decisions of young patients with breast cancer.3
Accordingto theAmericanSocietyofClinicalOncologyand
EuropeanSociety forMedicalOncologyguidelines, embryoor
oocyte cryopreservation is the standard procedure for fertil-
ity preservation in patients with cancer.4,5 No proven meth-
ods for preservationof ovarian function are yet available. The
administrationof luteinizinghormone–releasinghormoneana-
logues (LHRHa)during chemotherapy is consideredanexperi-
mental strategy to preserve ovarian function and fertility,
mainly because of the lack of data on long-termovarian func-
tion and pregnancies.4,5 Moreover, owing to both the pos-
sible detrimental effect of the lack of chemotherapy-induced
amenorrhea on prognosis6 and data suggesting potential an-
tagonism with concurrent administration of antiestrogen
therapyandchemotherapy,7-9 thereareconcernsas towhether
the concomitant use of LHRHa and chemotherapy in patients
with endocrine-sensitive breast cancer compromisesdisease-
free survival (DFS).10
Previous results of the randomized phase 3 PROMISE-
GIM6 (Prevention of Menopause Induced by Chemotherapy:
a Study in Early Breast Cancer Patients—Gruppo Italiano
Mammella 6) study showed that temporary ovarian suppres-
sion during chemotherapy induced by the LHRHa triptorelin
significantly reduced theoccurrenceof treatment-relatedearly
menopause (defined as no resumption of menstrual activity
andpostmenopausal levelsof follicle-stimulatinghormoneand
estradiol for 1 year after the last cycle of chemotherapy) from
25.9% to 8.9% (odds ratio [OR], 0.28 [95% CI, 0.14-0.59];
P < .001) without increasing the incidence of LHRHa-related
toxicities, suchashot flushes,headache, sweating,moodmodi-
fication, andvaginal dryness.11 In the current analysis,wepre-
sent long-term outcome results, focusing on long-term ovar-
ian function, pregnancies, and DFS.
Methods
Study Design and Patients
Details of thePROMISE-GIM6studydesign and results for pri-
mary outcomes have been previously reported.11 Briefly, the
studywas amulticenter, randomized, open-label, phase 3 su-
periority trial aiming to address the effect of temporary ovar-
ian suppression obtained by administering the LHRHa trip-
torelinbeforeandduringchemotherapyasa strategy to reduce
the occurrence of early menopause in young women with
breast cancer undergoing adjuvant or neoadjuvant chemo-
therapy. The trial protocol is available in Supplement 1.
Eligiblepatientswerewomenaged18to45yearswithstage
I to III breast cancer who were premenopausal at the time of
diagnosis. Premenopausal status was defined at baseline as
presence of activemenstrual cycles or normalmenses during
the 6 weeks before the start of chemotherapy. Patients with
either hormone receptor–positive or hormone receptor–
negative tumors were eligible. Tumors were defined as hor-
mone receptor–positive by a finding of at least 1% of positive
cells for estrogen receptor, progesterone receptor, or both,
evaluated by immunohistochemistry analysis.
The study was conducted in 16 Italian centers by the
Gruppo ItalianoMammella (GIM) andwas approvedby ethics
committees of all participating institutions. Written in-
formed consent was obtained from all patients before study
entry.
Randomization and Blinding
Eligible patients were randomly allocated to receive chemo-
therapyalone (controlgroup)orchemotherapyplus theLHRHa
triptorelin (LHRHagroup).Randomizationwasperformedcen-
trally by faxing the Clinical Trials Unit of the National Insti-
tute forCancerResearch inGenoa (Italy).11Randomization lists
werestratifiedbycenterandwerepreparedwith theuseofper-
muted blocks of different sizes, with a 1:1 allocation ratio. All
data were collected centrally at the clinical trials unit of the
National Institute for Cancer Research in Genoa (Italy).
Study Procedures
In patients randomized to receive LHRHa, triptorelin
(3.75 mg) was administered intramuscularly at least 1
week before chemotherapy and then every 4 weeks for
the duration of chemotherapy. Patients received chemo-
therapy according to one of the following regimens: anthra-
cycline plus taxane-based, anthracycline-based, or CMF
(cyclophosphamide-methotrexate-fluorouracil)-based.11
Women with hormone receptor–positive disease received
adjuvant endocrine therapy for 5years starting fromtheendof
chemotherapy. In both study groups, patients who resumed
their ovarian function during the 12-month period of observa-
tionafter theendofchemotherapyoratanytimeduring the fol-
lowing 5 years of follow-upwere allowed to receive LHRHa for
at least 2 years as part of their endocrine treatment.
Radiation therapy after completion of chemotherapy was
mandatory for patients who underwent a lumpectomy. For
patients who underwent a mastectomy, radiation therapy
was performed according to the guidelines of each participat-
ing institution.
Study Objectives and End Points
Detailsandresultsontheprimaryobjectives (ie, chemotherapy-
induced earlymenopause andadverse events) havebeenpre-
viously reported.11 The aim of the present post hoc extension
of the original study designwas to investigate the association
between treatment groups and long-termoutcomes (ie, long-
term ovarian function, pregnancies, and DFS).
Long-term ovarian function was evaluated by yearly as-
sessmentofmenstrual activity at the timeof clinicvisits.Ovar-
ian functionwas defined as having resumed based on the oc-
currence of at least 1 menstrual cycle. Pregnancies were
evaluatedduring annual follow-upvisits, andpatients report-
ing no pregnancy were asked about the reasons (eg, preg-
nancynotdesiredor failedattempt). Patientswho reportedat-
termorpretermdelivery,miscarriage, and/or inducedabortion
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were considered as having a pregnancy. DFS events were de-
fined by the occurrence of one of the following: local recur-
rence,distantmetastases, contralateral or ipsilateral breast tu-
mor, second primary malignancy, or death from any cause.
Systematicdatacollectionwasbasedontheannualfollow-up
visit, includingphysical examinationandmammography,per-
formed by each patient according to clinical practice.
Statistical Analysis
Samplesizecalculationsandstatistical assumptions for thepri-
maryobjectiveof thestudywerepreviouslydescribed.11Briefly,
the trialwasdesigned todetect a20%absolute reduction (from
60% to 40%) in the incidence of early menopause in the ex-
perimental group, with a power of 90% and a 2-sided α error
of 5%. Analyses on long-term ovarian function, pregnancies,
and DFS were not preplanned in the study protocol, and the
power of the statistical analyses for these endpointswerenot
prespecified; thus, results are exploratory.
Time to recovery of ovarian function was defined as the
interval from the randomization to the occurrence of men-
strual resumption. Five-year cumulative incidence of men-
strual resumption included patients who resumedmenses at
any time (ie,within or beyond 12months after the end of che-
motherapy). Time to pregnancy was the interval from ran-
domization to the start of the first pregnancy, independent of
itsoutcome.Only the firstpregnancyforeachpatientwas taken
into account.DFS intervalwas computed fromthedateof ran-
domization to the date of the first occurrence of a DFS event.
For each endpoint, observation times of patientswithout the
eventwere censored on the date of their last contact. The last
annual follow-upvisit recordedwasperformedonJune3,2014.
An administrative censoring at the cut-off date of December
31, 2013, was applied to all time-to-event analyses. No event
was observed between the cutoff date and the last annual
follow-up visit for each analyzed outcome.
All reported statistical analyses were based on the study
intention-to-treatpopulation.Themedianperiodof follow-up
and its interquartile rangewere calculated for the entire study
cohort according to the reverseKaplan-Meiermethod.Thecu-
mulative incidence of menstrual resumption and pregnancy
were estimated accounting for disease recurrence, second tu-
mor, and death fromany cause as competing risk events. DFS
probability was computed according to the Kaplan-Meier
method. The CIs of survival time probabilities were calcu-
lated according to the log-log method. As estimates of treat-
ment effect, unadjustedandadjustedhazard ratios (HRs)with
95% CIs were calculated with the Fine and Graymodel in the
presenceofcompeting risksandwith theCoxproportionalhaz-
ardsmodel otherwise. AnHRgreater than 1 indicates that the
useofLHRHa increased theprobabilityofdevelopinganevent
(ie, resumption ofmenstrual activity, pregnancy, DFS event).
In themultivariablemodel, because of the limited number of
analyzed events, only the covariates with known prognostic
association (ie, tumor size,nodal status,hormone receptor sta-
tus)were included.Multivariable analyseswereperformedaf-
ter single imputationofmissing values in 7 cases. Thepropor-
tional hazards assumption was checked assessing the
Schoenfeld plot.
Subgroupanalyses ofDFSwereperformedbymeansof an
interaction test to determine the consistency of the treat-
menteffectontheoutcomeaccording tohormonereceptor sta-
tus (positive and negative). The likelihood ratio testwas used
to test the statistical significanceof all coefficients.No adjust-
ment formultiple testingwas applied. Because the studywas
conducted in 16 centers, all the analyses were repeated after
adjustment for clustering (eResults in Supplement 2).
All statistical tests were 2-sided, and P values of .05 or
lesswere considered statistically significant. Statistical analy-
ses were performed (L. B.) using SAS 9.2 (SAS Institute).
Results
Between October 24, 2003, and January 14, 2008, a total of
281 patients (median age, 39 [range, 24-45] years) were en-
rolled in the study.Figure 1 shows the trial profile. At the time
Figure 1. The PROMISE-GIM6 Trial Profile
281 Patients randomized
133 Randomized to receive
chemotherapy alone
127 Received chemotherapy alone
as randomized
6 Did not receive chemotherapy
as randomized (refused after
randomization)
148 Randomized to receive
chemotherapy plus triptorelin
146 Received chemotherapy plus
triptorelin as randomized
2 Did not receive chemotherapy
plus triptorelin as randomized
1 Refused after allocation
1 Refused after first dose
of triptorelin
86 Completed last follow-up visit
47 Did not complete last follow-up visit
29 Experienced disease progression
18 Lost to follow-up a
95 Completed last follow-up visit
53 Did not complete last follow-up visit
36 Experienced disease progression
17 Lost to follow-up a
133 Included in current analysis (long-
term ovarian function, pregnancies,
disease-free survival) b
148 Included in current analysis (long-
term ovarian function, pregnancies,
disease-free survival) b
The number of patients screened for
eligibility, the number of patients
excluded, and the reasons for
exclusion were not recorded.
a Patients without clinical information
after December 31, 2012.
bDisease-free survival interval was
computed from the date of
randomization to the date of local
recurrence, distant metastases,
contralateral or ipsilateral breast
tumor, second primary malignancy,
or death from any cause, whichever
occurred first. Observation times of
patients without event were
censored on the date of last
contact.
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of the current analysis, a total of 35 patients (12.5%)were lost
to follow-up, 17 of 148 (11.5%) in the LHRHa group and 18 of
133 (13.5%) in the control group. At the study cutoff date, De-
cember 31, 2013, median follow-up time was 7.3 years (inter-
quartile range, 6.3-8.2 years).
Baselinepatient and tumorcharacteristicswere similarbe-
tween treatment groups, as well as chemotherapy adherence
(Table 1).A totalof226patients (80.4%)hadhormonereceptor–
positive tumors, and themajorityof them(92.9%) receivedad-
juvantendocrine therapyafter chemotherapy (Table 1).Among
226 women with hormone receptor–positive disease, 158
(69.9%) received adjuvant LHRHa, 79 of 117 (67.5%) in the
LHRHa group and 79 of 109 (72.5%) in the control group
(Table 1).
Long-termOvarian Function
Menstrual resumption at any time occurred in 116 of 148 pa-
tients (incidence rateper 100person-years, 32.4 [95%CI, 26.7-
38.8]) in the LHRHa group and in 96 of 133 patients (inci-
dence rate per 100 person-years, 26.0 [95% CI, 21.0-31.7]) in
the control group.
The 5-year cumulative incidence estimate of menstrual
resumption was 72.6% (95% CI, 65.7%-80.3%) in the LHRHa
group and 64.0% (95% CI, 56.2%-72.8%) in the control
group (HR, 1.28 [95% CI, 0.98-1.68]) (P = .07) (Figure 2). The
age-adjusted estimate of HR was 1.48 (95% CI, 1.12-1.95;
P = .006).
Among patients with hormone receptor–positive tumors,
the 5-year cumulative incidence estimate of menstrual
resumption was 69.3% (95% CI, 61.4%-78.2%) in the LHRHa
group and 60.7% (95% CI, 52.2%-70.7%) in the control group
(HR, 1.25 [95% CI, 0.93-1.68]). Among patients in the hor-
mone receptor–negative subgroup, the 5-year cumulative
Table 1. Baseline Patient and Tumor Characteristics and Treatments
Administered by Study Group
Characteristic
No. (%)
Control
Group
(n = 133)
LHRHa Group
(n = 148)
Age, median (range), y 39 (25-45) 39 (24-45)
Age distribution, y
<30 5 (3.8) 8 (5.4)
30-34 23 (17.3) 23 (15.5)
35-39 45 (33.8) 46 (31.1)
40-44 57 (42.9) 66 (44.6)
45-49 3 (2.3) 5 (3.4)
Full-term pregnancies before
breast cancer diagnosis, No.
0 51 (38.3) 49 (33.1)
≥1 78 (58.6) 96 (64.9)
Unknown 4 (3.0) 3 (2.0)
Tumor size (T)
pT1 75 (56.4) 90 (60.8)
pT2 51 (38.3) 51 (34.5)
pT3-4 3 (2.3) 5 (3.4)
Unknown 4 (3.0) 2 (1.4)
Axillary nodes (N)
pN0 67 (50.4) 61 (41.2)
pN1 44 (33.1) 58 (39.2)
pN2 18 (13.5) 27 (18.2)
Unknown 4 (3.0) 2 (1.4)
Tumor grade (G)
G1 5 (3.8) 15 (10.1)
G2 57 (42.9) 50 (33.8)
G3 60 (45.1) 73 (49.3)
Unknown 11 (8.3) 10 (6.8)
Hormone receptor status
ER-negative and PR-negative 22 (16.5) 29 (19.6)
ER-positive, PR-positive,
or both
109 (82.0) 117 (79.1)
Unknown 2 (1.5) 2 (1.4)
Timing of chemotherapy
Adjuvant therapy 117 (88.0) 133 (89.9)
Neoadjuvant therapy 10 (7.5) 13 (8.8)
Not begun 6 (4.5) 2 (1.4)
Type of chemotherapy
Anthracycline-based 57 (42.9) 56 (37.8)
Anthracycline- and
taxane-based
62 (46.6) 86 (58.1)
CMF-based 8 (6.0) 4 (2.7)
Cumulative cyclophosphamide dose,
median (IQR), mg/m2
4008
(3624-5550)
4080
(3697-5400)
Duration of chemotherapy,
median (IQR), wk
16.9
(15.0-21.3)
17.8
(15.0-21.3)
Treatment completed as planned
Chemotherapy 121 (91.0) 143 (96.6)
LHRHa during chemotherapy NA 142 (95.9)
(continued)
Table 1. Baseline Patient and Tumor Characteristics and Treatments
Administered by Study Group (continued)
Characteristic
No. (%)
Control
Group
(n = 133)
LHRHa Group
(n = 148)
Type of adjuvant endocrine therapy
in hormone receptor–positive patientsa
No treatment 6 (5.5) 10 (8.6)
LHRHa alone 3 (2.8) 4 (3.4)
LHRHa + tamoxifen 65 (59.6) 65 (55.6)
LHRHa + aromatase inhibitor 11 (10.1) 10 (8.6)
Tamoxifen 22 (20.2) 28 (23.9)
Tamoxifen followed by aromatase
inhibitor
2 (1.8) 0 (0.0)
Duration of endocrine therapy,
median (IQR), y
5.00
(4.78-5.03)
5.00
(4.96-5.10)
Duration of adjuvant LHRHa,
median (IQR), y
4.10
(2.08-5.04)
4.08
(2.06-4.92)
Abbreviations: CMF, cyclophosphamide, methotrexate, fluorouracil;
ER, estrogen receptor; IQR, interquartile range; LHRHa, luteinizing
hormone–releasing hormone analogues; NA, not applicable;
PR, progesterone receptor.
a Percentages calculated on the total number of patients with hormone
receptor–positive disease (117 in the LHRHa group and 109 in
the control group).
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incidence estimate of menstrual resumption was 86.2% (95%
CI, 74.5%-99.7%) in the LHRHa group and 81.0% (95% CI,
65.8%-99.6%) in the control group (HR, 1.41 [95% CI, 0.76-
2.65]) (P = .73 for interaction). The age-adjusted estimates of
HR were 1.46 (95% CI, 1.07-2.00) among women with hor-
mone receptor–positive tumors and and 1.44 (95% CI, 0.75-
2.76) among those with hormone receptor–negative tumors
(P = .97 for interaction).
Pregnancies
At the censoring date, 8 pregnancies (incidence rate per 100
person-years, 0.9 [95% CI, 0.4-1.8]) occurred among the 148
patients enrolled in the LHRHa group and 3 pregnancies (in-
cidence rate per 100 person-years, 0.4 [95% CI, 0.1-1.1])
occurred among the 133 women in the control group. The
5-year cumulative incidence estimate of pregnancy was
2.1% (95% CI, 0.7%-6.3%) in the LHRHa group and 1.6%
(95% CI, 0.4%-6.2%) in the control group (HR, 2.56 [95% CI,
0.68-9.6]; P = .14). The age-adjusted estimate of HR was
2.40 (95% CI, 0.62-9.22; P = .20).
Among the 5 pregnancies occurringmore than 5 years af-
ter the end of chemotherapy, 4 occurred in the LHRHa group
and 1 in the control group (eFigure 1 in Supplement 2).
Of 11 pregnancies, 4 occurred in women with hormone
receptor–positive tumors (4 [3.4%] among the 117 patients in
the LHRHa group and 0 [0.0%] among the 109 women in the
control group) and 7 in patients with hormone receptor-
negative tumors (4 [13.8%]amongthe29patients in theLHRHa
groupand3 [13.6%]amongthe22womenin thecontrolgroup).
When the analysis was performed by excluding patients
whodeclared no attempt at pregnancy (43 patients [29.1%] in
theLHRHagroupand42patients [31.6%] in thecontrol group),
the HR was 2.48 (95% CI, 0.66-9.29) (P = .18).
None of the 8 offspringwere bornwith congenital abnor-
malities. One preterm delivery was observed in the LHRHa
group. eTable 1 in Supplement 2 shows pregnancy outcomes
in the 2 groups.
The interval fromrandomization to firstpregnancy ranged
between 1.0 and 6.6 years (6.2-6.6 years among women with
hormone receptor–positive tumors and 1.0-6.5 years among
those with hormone receptor–negative tumors).
Disease-Free Survival
At the study cutoff date, 65 events were observed in 281 pa-
tients (23.1%), 36 of 148 (24.3%) in the LHRHa group and 29
of 133 (21.8%) in the control group (eTable 2 in Supplement 2).
Five-yearDFSwas80.5% (95%CI, 73.1%-86.1%) in theLHRHa
group and 83.7% (95% CI, 76.1%-89.1%) in the control group
(Figure 3). The crude HR for DFS for the comparison of the
LHRHa group vs the control group was 1.17 (95% CI, 0.72-
1.92) (P = .52).
In patients with hormone receptor–positive disease,
5-year DFS was 85.1% (95% CI, 77%.2-90.5%) in the LHRHa
group and 85.2% (95% CI, 77.0%-90.7%) in the control
group (eFigure 2 in Supplement 2). In patients with hor-
mone receptor–negative disease, 5-year DFS was 62.1%
(95% CI, 42.1%-76.9%) in the LHRHa group and 76.2%
(95% CI, 51.9%-89.3%) in the control group (eFigure 3 in
Supplement 2).
Results from the Cox proportional hazard model, adjust-
ing for baseline disease stage and hormone receptor status,
showed no statistically significant difference in DFS among
treatment groups (HR, 1.10 [95% CI, 0.67-1.79]; P = .72)
(Table2).Noevidenceofproportionalhazardsassumptionvio-
lation was detected.
Subgroup analysis of DFS compared patients with hor-
mone receptor–positive tumors with patients with hormone
receptor–negative tumors. The HRs were 0.96 (95% CI,
0.55-1.70) for patients with hormone receptor–positive
tumors and 2.11 (95% CI, 0.74-5.98) for those with hormone
receptor–negative tumors, respectively (P = .19 for
interaction).
Discussion
Long-term results from the PROMISE-GIM6 study,11 after a
median follow-up of 7.3 years, show that concurrent admin-
istration of triptorelin and chemotherapy, compared with
chemotherapy alone, was associated with higher long-term
probability of menstrual resumption. Of a total of 11 preg-
nancies, 8 were reported by women in the LHRHa group
and 3 by women in the control group, a nonsignificant dif-
ference. There was a higher risk of inferior DFS for women
assigned to the LHRHa group that did not reach statistical
significance; this increased but statistically nonsignificant
risk appeared specific to the patients with hormone
receptor–negative tumors.
The PROMISE-GIM6 study has longer follow-up than
other studies that have evaluated the role of LHRHa as a
strategy to preserve ovarian function during chemotherapy
in young patients with early breast cancer. Seven other ran-
domized studies have been published on the same issue in
breast cancer patients,12-18 and another trial has been pre-
sented at the 2010 ASCO Annual Meeting (eTable 3 in
Figure 2. Cumulative Incidence Estimate ofMenstrual Resumption
in the Treatment Groups
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Supplement 2).19 Recently, the final results of another large
randomized study, the POEMS-SWOG S0230 trial, have
been published.20 The POEMS-SWOG S0230 trial differs
from our study in that it included only patients with hor-
mone receptor–negative disease, and thus no adjuvant
endocrine therapy was administered; the primary end point
of the study, premature ovarian failure, was defined as 6
months of amenorrhea and follicle-stimulating hormone
levels in the postmenopausal range at 2 years; and goserelin
was the LHRHa used.20 The most recent systematic review
and meta-analysis on this topic showed that ovarian sup-
pression with LHRHa during chemotherapy was associated
with a higher rate of ovarian function recovery after 6
months (OR, 2.41; P = .002) and at least 12 months (OR, 1.85;
P < .001) following the last chemotherapy cycle.21 However,
because randomized trials reported conflicting results and
the meta-analyses on this issue have the limitation of com-
bining trials with different end points and methods, there is
still active debate on the efficacy of this strategy.22,23 More-
over, concerns persist about the lack of long-term follow-up
data supporting the safety of ovarian suppression, espe-
cially for women with endocrine-sensitive breast cancer.6-10
For all these reasons, the 2013 American Society of Clinical
Oncology and European Society for Medical Oncology
guidelines do not recommend the use of this strategy as a
reliable means of preserving ovarian function and fertility in
young patients with cancer.4,5
The majority of trials evaluating ovarian suppression
during breast cancer chemotherapy have reported prema-
ture ovarian failure rates at a short follow-up, variable
between 6 and 36 months, and there is paucity of data avail-
able at longer time points (eTable 3 in Supplement 2). In the
current analysis, we showed that LHRHa treatment was
associated with an increased probability of menstrual
resumption at a long-term follow-up (median follow-up, 7.3
years), although the absolute difference (8.6%) between the
2 groups was modest and lower than that observed 12
months after the end of chemotherapy (13.7%), as described
in the primary trial report.11
Recently, the POEMS-SWOG S0230 study showed a sta-
tistically significant higher number of pregnancies in the
LHRHa group as compared with the control group (22 vs 12
pregnancies; OR, 2.45; P = .03).20 Our results are consistent
with those of the POEMS-SWOG S0230 study, demonstrat-
ing a higher although not statistically significant difference
Figure 3. Disease-Free Survival in the Treatment Groups
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Table 2. Multivariable Cox Proportional HazardsModel: Effect of Temporary Ovarian Suppression, Tumor Size, Axillary Nodes, and Hormone Receptor
Status on Disease-Free Survivala (N=281)b
Variable
No.
HR (95% CI) P ValuedPatients
Disease-Free Survival
Eventsc
Random assignment
Control 133 29 1 [Reference]
.72
LHRHa 148 36 1.10 (0.67-1.79)
Tumor size (T)
pT1 167 33 1 [Reference]
.39
pT2-4 114 32 1.25 (0.76-2.05)
Axillary nodes (N)
pN0 133 22 1 [Reference]
.03
pN1-2 148 43 1.80 (1.06-3.05)
Hormone receptor status
ER-negative and PR-negative 53 17 1 [Reference]
.05ER-positive, PR-positive,
or both
228 48 0.56 (0.32-0.97)
Abbreviations: CI, confidence interval; ER, estrogen receptor; HR, hazard ratio;
LHRHa, luteinizing hormone–releasing hormone analogues; PR, progesterone
receptor.
a Disease-free survival interval was computed from the date of randomization
to the date of the occurrence of an event. Observation times of patients
without a disease-free survival event were censored on the date
of last contact.
bAfter single imputation of missing values on at least 1 covariate in 7 patients.
c Disease-free survival event was defined by the occurrence of local recurrence,
distant metastases, contralateral or ipsilateral breast tumor, second primary
malignancy, or death from any cause, whichever occurred first.
d Likelihood-ratio test.
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in pregnancy in the LHRHa group. The lower number of
pregnancies in our trial compared with the POEMS-SWOG
S0230 study could be explained by the fact that the POEMS-
SWOG S0230 study enrolled only patients with hormone
receptor–negative tumors, whereas the majority of patients
in our trial had hormone receptor–positive disease. Most
hormone receptor–positive patients received adjuvant
endocrine therapy for at least 5 years and delayed preg-
nancy attempts for at least 6 months after the end of endo-
crine therapy.
The concerns about the safety of the concurrent adminis-
tration of LHRHa and chemotherapy rely on both the pos-
sible detrimental effect of the lack of chemotherapy-induced
amenorrhea on prognosis6 and the potential negative interac-
tion between the 2 treatments, especially for patients with
endocrine-sensitive tumors.7,8 Because of these concerns,
only patients with hormone receptor–negative disease have
been included in the majority of the trials.14,16,19,20 On the
first point, data suggest that chemotherapy-induced amenor-
rhea is associated with improved outcomes in young patients
with breast cancer.6 It can be hypothesized that the resump-
tion of ovarian function, with the subsequent estrogen pro-
duction, might adversely affect survival. This concern was
addressed in our trial by allowing initiation of LHRHa at the
time of restoration of ovarian function as part of adjuvant
endocrine treatment. A total of 92.9% of patients with
endocrine-sensitive tumors received adjuvant hormonal
therapy, and 69.9% of them received LHRHa as part of the
endocrine treatment. The other concern about the potential
detrimental effect of concurrent administration of endocrine
therapy and chemotherapy is based on both preclinical data
suggesting a potential antagonism between tamoxifen and
chemotherapy7,8 and clinical data from the SWOG 8814 INT-
0100 randomized study suggesting a DFS advantage with use
of sequential, as compared with concurrent, tamoxifen and
chemotherapy in postmenopausal women with breast
cancer.9 However, the mechanism of action of LHRHa is dif-
ferent from that of tamoxifen, and results from randomized
trials did not demonstrate any difference in the prognosis of
patients undergoing chemotherapy alone or with concurrent
ovarian suppression.24-26 These data are consistent with the
recently reported excellent DFS results of the TEXT (Tamoxi-
fen and Exemestane Trial) study with triptorelin adminis-
tered concurrently with chemotherapy in patients with hor-
mone receptor–positive tumors.27
Our secondary analysis of the PROMISE-GIM6 trial has
demonstrated that in patients with hormone receptor–
positive disease, DFS was not statistically significantly differ-
ent between the 2 groups (HR, 0.96). However, in those
patients who resumed ovarian function after chemotherapy,
treatment with LHRHa was advised as part of adjuvant endo-
crine therapy.28 In the subgroup of patients with hormone
receptor–negative tumors, women randomized to LHRHa
had 5-year DFS of 62.1%, whereas those randomized to con-
trol had 5-year DFS of 76.2%, with an HR of 2.11. Although
this result was not statistically significant, the study included
only 53 patients with hormone receptor–negative disease and
therefore may have been underpowered to detect outcome
differences in this subgroup. Moreover, the lack of statistical
significance for the test for interaction (P = .19) also could
represent underpowering. This finding is discordant with the
results of the POEMS-SWOG S0230 study, which demon-
strated superior DFS in 105 women treated with LHRHa in
addition to chemotherapy (4-year DFS, 89%) as compared
with 113 women treated with chemotherapy alone (4-year
DFS, 78%), with an HR of 0.49 (P = .04).20 Except for the dif-
ferent median follow-up (4.1 years in POEMS-SWOG S0230
and 7.3 years in PROMISE-GIM6), there are no other apparent
differences able to explain the observed discrepancy
between the 2 trials. The discordance between our finding
and that of the POEMS-SWOG S0230 trial, and the potential
for breast cancer recurrence beyond 5 years, underscores the
importance of obtaining data on long-term recurrence and
mortality by hormone receptor status for all participants in
trials evaluating preservation of fertility.
The main limitation of this update of the PROMISE-
GIM6 study is that the analyses were not prespecified in the
study protocol and the decision to collect long-term out-
comes was planned at the time of the primary end point
analysis, with annual systematic follow-up.11 In particular,
data on patients’ intention or desire to become pregnant
were available only in a minority of patients. Moreover, the
trial was not powered to assess prespecified differences in
these end points and to study interactions in the subgroup
analyses. Because of these limitations, our results should be
considered exploratory. However, they add useful new infor-
mation about the role of LHRHa for preservation of ovarian
function. As compared with the POEMS-SWOG S0230 study,
our data suggest that this strategy could be useful and safe
not only in women with hormone receptor–negative breast
cancer, as recently endorsed by the 2015 St. Gallen Interna-
tional Expert Consensus panel and the National Comprehen-
sive Cancer Network guidelines,29,30 but also for those with
hormone receptor–positive tumors, who account for the
majority (ie, more than 65%) of new cases of breast cancer in
young women.31,32
Our results, together with the findings from the POEMS-
SWOGS0230study, indicate that, inaddition to fertilitypreser-
vationstrategiessuchasembryoandoocytecryopreservation,4,5
temporaryovariansuppressionwithLHRHa isanoptiontopre-
serve ovarian function in premenopausal women with early
stage breast cancer receiving adjuvant chemotherapy.
Conclusions
Among premenopausal women with either hormone
receptor–positive or hormone receptor–negative breast can-
cer, concurrent administration of triptorelin and chemo-
therapy, compared with chemotherapy alone, was associ-
ated with higher long-term probability of ovarian function
recovery, without a statistically significant difference in
pregnancy rate. There was no statistically significant differ-
ence in DFS for women assigned to triptorelin and those
assigned to chemotherapy alone, although study power was
limited.
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